THURSDAY, SEPTEMBER 29, 2016

Vaxxas

47 Thorndike St
Cambridge, MA - 02141

Vaxxas News

Vaxxas set to develop Nanopatch 'needle-free' vaccines

Vaxxas said this week that it has raised $20 million for a series of clinical programs toward development of a line of vaccine products using the company's Nanopatch platform, which utilizes painless microneedles. Read More »

Vaxxas secures $20 million for Nanopatch vaccine programs

Biotechnology company Vaxxas said on Monday that it has obtained $20 million in equity funding from new and existing investors. Read More »